跳到正文
ISPE iSpeak 专家博客·· 4 天前AI 评分52

ISPE 澳大拉西亚分会线上活动梳理生命科学 AI 落地的前提与验证评估要点

Life Sciences AI Reality Check: Turning AI Conversations into Action: An ISPE Australasia Affiliate Virtual Event

AI 导读

ISPE 澳大拉西亚分会于 2026 年 9 月举办线上活动,四位 AI 讲者讨论生命科学行业负责任实施 AI 所需的前提。讨论认为落地成效取决于组织准备度、数据治理与信任而非技术本身,数据须具备代表性、完整性与可治理性。围绕大语言模型评估,讲者指出传统 GxP 计算机系统验证不足以单独覆盖,需加入输入控制、护栏与人工介入阈值,并提及 ISPE GAMP 指南与 EU GMP Annex 22。

正文 · 原文

There are moments when an industry conversation shifts.

Not gradually. Not quietly.

A moment when you can almost feel a collective realization settling across a room. The questions become sharper. The discussion becomes more practical. The focus moves from possibility to responsibility.

That shift was on full display during the Life Sciences AI Reality Check, a virtual event hosted by the ISPE Australasia Affiliate in September 2026. Four AI experts came together to explore a pressing question: what does it take to implement artificial intelligence (AI) responsibly in the life sciences industry? Across the presentations and panel discussion, one message clearly stood out: successful adoption depends as much on organizational readiness, data governance, and trust as it does on the technology itself.

What unfolded was more than a series of presentations. It was a dynamic exchange of ideas connecting biomedical data science, pharmaceutical quality systems, autonomous validation and AI governance. The audience participation helped shape the conversation, steering it from discussions of emerging possibilities toward the practical foundations needed for safe, credible and sustainable AI adoption.

Four Perspectives, One Shared Challenge

The four speakers approached responsible AI implementation from complementary perspectives:

Milica Ng, PhD

Strategic and Scientific Advisor, Actimo Labs

“From Mechanistic Models to Agentic AI: Building Data-Centric, Governed Life Sciences Organisations”

Brad Swarbrick

Managing Director, KAX Group

“The Role of Artificial Intelligence and Machine Learning in Modern Pharmaceutical Quality Systems”

RK Neelakandan

AI Quality and Safety, Healthcare and Lifesciences, Google

“Autonomous Validation for Life Sciences Systems”

Martin Heitmann

Managing Director, MH Consulting & Advisory GmbH

“AI Governance and AI in GxP: GAMP®'s Contribution, the EU GMP Annex 22 and Future Perspectives”

This presentation drew on the speaker’s work as a Co-Lead of the ISPE GAMP® Guide: Artificial Intelligence and as a topic lead in the Europe Medicine Agency’s Interested Parties working group on Annex 22

Beyond the AI Hype

AI has become impossible to ignore. Yet for organizations operating in regulated Life Sciences environments, excitement alone is not enough. The discussion quickly moved beyond technology trends to the realities of implementation: defining a meaningful use case, understanding the process, preparing representative data, establishing governance and ensuring that people remain accountable for critical decisions.

A recurring message was that AI should enhance human expertise, not replace it. Agentic AI, machine learning, digital twins and large language models may expand what is possible, but reliable outcomes still depend on context, critical thinking, subject matter expertise and organisational readiness.

Data Remains the Foundation

High-quality, fit-for-purpose data emerged as the common thread running through every topic. Organizations cannot expect meaningful outcomes if their data lacks context, integrity, representativeness or effective governance. The challenge is not simply to own more data, but to understand it, control it and make it usable across organisational boundaries that are often fragmented or siloed.

Rethinking Validation for Dynamic Systems

The conversation also challenged traditional ideas of validation. AI-enabled systems may learn, evolve or behave differently depending on their inputs and operating context. This makes one-time assurance increasingly difficult to rely on. The speakers explored the need for model-specific evaluation, controls over inputs and behavior, defined guardrails, ongoing monitoring, auditable decision pathways and clear points for human intervention.

Despite the novelty of the technology, the discussion repeatedly returned to principles familiar to every life sciences professional: product quality, patient safety, data integrity, transparency and accountability.

From Presentations to Practical Questions

The individual presentations established the landscape; the panel discussion brought it into focus. As questions moved from business need to model design, evaluation and trust, the speakers tested the ideas against the practical realities faced by Life Sciences organizations. Their responses converged on four themes: organizational readiness, the selection and use of models, evaluation and trust.

The following questions and responses capture that discussion.

Q. What is the most challenging part of turning a business need or opportunity into an AI based model?

Ng: shared that the biggest challenge is culture, people, and trust in the AI model. Organizations, especially life science organisation are siloed and data is fragmented. There is low level of data and technology maturity which becomes the biggest challenge in designing reliable and trustworthy AI models.

Neelakandan: further added that : an organizational shift is required. Life sciences companies need to move beyond simply owning data and establish effective data governance. Quality control of input data is essential to the design, training and validation of AI models, and ultimately to demonstrating compliance. This requires cross-functional cooperation and an honest alignment between organisational intent and operational capability.

Heitmann: also noted that AI implementation begins well before a model is designed. Organizations should first ask, "What company challenge can AI help address?" If an existing process already performs effectively with established workflows and controls, introducing AI may not be necessary. Organizations must also consider whether they can realistically support the proposed use throughout its lifecycle.

Takeaway: 

Successful AI implementation in the life sciences sector begins before a tool is selected. Organizations first need to understand the process and business problem, assess their data quality and governance, and determine whether their people and operating model are ready to support the proposed use. Implementing AI without that foundation is likely to fail.

Q: What is the most important thing to consider or is the most overlooked element during the design of AI models?

Swarbrick: stated that it is important to get a clear understanding of the processes, e.g., flow, bottlenecks, and data. We should ensure that we have representative data that can be used for designing the AI model. Data without homogeneity is of little value in building compliant AI systems.

Heitmann: added that decision making and explaining how the AI model arrives at a particular output/decision is usually the trickiest part.

Takeaway: 

Effective AI model design starts with clear specifications grounded in a detailed understanding of the organization's processes, bottlenecks and available data. The model must use representative data, and its benchmarks, outputs and decision criteria must be explainable and justifiable.

Q: What does the large language modeling (LLM) system evaluation look like?

Neelakandan: mentioned that evaluation requirements depend on the type of system—for example, retrieval-augmented generation (RAG) and agentic AI require different approaches. Conventional GxP validation methods are not sufficient on their own for these models. Evaluation and testing should extend beyond the final output to include controls over inputs and model behaviour. Establishing appropriate guardrails can also make the basis for decisions easier to justify.

Swarbrick: added that for life cciences manufacturing operations, organizations should consider customized LLMs with company-specific guardrails, rules and firewalls. Where a generative AI system is introduced, a firewall between the company LLM and the external system should protect company data and preserve control over outcomes.

Takeaway: 

Traditional GxP computer-system validation approaches are not sufficient on their own for evaluating AI models. Organizations need a strategy for evaluation suited to the model type, supported by company-specific processes, customized controls and guardrails that govern inputs and decision pathways rather than focusing only on final outputs.

Q: What is required to build trust in AI models once they are designed and ready for implementation?

Swarbrick: said that it is important to use AI models for process improvements and keep them away from quality release decisions.

Neelakandan: added that operational rigor should be built through three controls: limitation mapping, including confidence, predictability and error levels; deterministic fallback pathways that require human intervention when confidence falls below an agreed threshold; and auditability, so the organization can explain and demonstrate how the AI model reaches decisions.

Heitmann: also emphasized that transparency, change management and a different vendor–supplier model are essential. AI implementation should be governed through the organization’s change management process. Greater transparency between organizations and service providers is needed to identify, assess and explain each model’s limitations, uncertainties and constraints. As a result, quality agreements between organizations and vendors will need to evolve.

Takeaway: 

Trust in AI models is earned through disciplined implementation, not speed of execution. It depends on high-quality inputs, clearly mapped limitations, defined thresholds for human intervention, auditable decision pathways, effective change management and more transparent relationships between organizations and their service providers.

Q: The tech industry is good at sharing resources on Github, regulators are good at setting rules, and LLMs are good at following rules. Are there any efforts to set up a global community that combine these strengths so all life science organizations can leverage the knowledge?

Heitmann: said that it is a very forwarding thinking idea and subject to legal implications and other agreements, ISPE may consider this initiative. A community of this kind would function as a repository of skills, guardrails and rules applicable to AI.

Neelakandan: further added that a shared community could provide a useful foundation for AI implementation, but it would not replace organization-specific assessment and accountability. Each organization would still need to understand its processes, define its validation requirements and remain responsible for how AI is used.

Cautiously Optimistic

As the event came to a close, one phrase captured the mood: “cautiously optimistic.”

Optimistic, because AI has the potential to accelerate innovation, improve decision-making, strengthen manufacturing processes and unlock new insights. Cautious, because the life sciences industry operates in a world where trust matters and every decision ultimately connects back to quality, safety, and integrity.

Taken together, the discussion presented AI implementation as an organizational capability rather than a stand-alone technology project. Life sciences organizations need clearly defined use cases, governed and representative data, risk-based evaluation, transparent decision pathways and explicit human oversight. The technology may be new, but the foundations remain familiar: understand the process, define accountability and build quality into the system from the outset.

Building the Future Together

The event demonstrated that the industry is ready for deeper, more practical conversations about AI. Organizations may be at different points in their journey, but many are asking the same questions: Where should we begin? How do we know the data is ready? What does proportionate assurance look like? How do we build trust without slowing responsible innovation?

By bringing together experts and practitioners from across disciplines and geographies, the ISPE Australasia Affiliate created a space to share knowledge, challenge assumptions and move the conversation forward. The lasting message was not that AI offers an easy path, but that responsible progress is possible when technology, quality, governance and human judgement advance together.

Learn More About the Australasia Affiliate

来源:ISPE iSpeak 专家博客 · ispe.org